OXGENE, which became a WuXi Advanced Therapies company in March 2021, provides end-to-end contract services to cell and gene therapy companies seeking to discover, develop, manufacture and test innovative drug candidates at scale for global commercialization. OXGENE provides rapid services through proprietary technology and automation platforms for molecular discovery and by integrating the full suite of technologies needed for cell and gene therapy manufacturing. OXGENE is known for its expertise in designing DNA sequences, optimizing expression of proteins, developing cell lines, and improving viral delivery systems. For more information, please visit www.oxgene.com
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.